Table 1.
Baseline Characteristics of the Study Population
| Characteristic | Study Cohort n=331 | No AF n=179 (54%) | PAF n=129 (39%) | PeAF n=23 (6.9%) |
|---|---|---|---|---|
| Female, n (%) | 75 (22.7) | 43 (24) | 30 (23) | 2 (8.6) |
| Age, mean yearsa | 57.8±12.8 | 54.3±13.6 | 61.3±10.5 | 66.0±9.2 |
| Left ventricular ejection fraction, %a | 20.0±6.6 | 19.2±7.0 | 20.6±5.9 | 22.9±6.2 |
| LA volume >40 mL/m2, n (%) | 253 (76.4) | 128 (72.0) | 105 (81.4) | 20 (87.0) |
| PR interval >200 ms, %a | 11 | 8.7 | 14.8 | 30.4 |
| Ischemic cardiomyopathy, n (%)a | 124 (37.5) | 56 (31.2) | 54 (41.9) | 14 (60.9) |
| Valvular heart disease, n (%) | 225 (68.0) | 117 (65.3) | 91 (70.5) | 17 (73.9) |
| Hypertension, n (%) | 250 (75.5) | 135 (75.4) | 99 (76.7) | 16 (69.6) |
| Diabetes mellitus, n (%) | 163 (49.2) | 82 (45.8) | 69 (53.4) | 12 (52.1) |
| Thyroid disease, n (%) | 83 (24.8) | 36 (20.6) | 38 (29.5) | 8 (34.8) |
| Obstructive sleep apnea, n (%) | 99 (30.0) | 53 (30.0) | 38 (29.5) | 8 (34.8) |
| COPD, n (%) | 90 (27) | 44 (24.6) | 38 (29.5) | 8 (34.8) |
| CABG, n (%) | 111 (33.5) | 52 (29.1) | 48 (37.2) | 11 (47.8) |
| Baseline creatinine, mg/dL | 1.6±0.9 | 1.6±1.0 | 1.7±0.9 | 1.6±0.6 |
| Baseline albumin, g/dL | 3.5±0.5 | 3.5±0.6 | 3.6±0.5 | 3.6±0.5 |
AF indicates atrial fibrillation; CABG, coronary arterial bypass grafting; COPD, chronic obstructive pulmonary disease; LA, left atria; PAF, paroxysmal atrial fibrillation; PeAF, persistent or permanent atrial fibrillation.
a
P<0.05 for χ2 or ANOVA comparison between groups.